Tolerability of palbociclib in younger and older patients with advanced breast cancer
- 9 November 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (1) , 96-104
Abstract
Palbociclib is a small-molecule cyclin-dependent kinase 4/6 inhibitor used to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Patient-specific factors impacting dose reductions or discontinuations are unknown. The primary objective was to evaluate the association of age (p = 0.02). Differences in palbociclib dose reductions or treatment discontinuations secondary to neutropenia were not detected (35.4% vs. 42.4%, p = 0.55). Neither the total number of palbociclib dose reductions (none: 54.2% vs. 49.1%, one: 33.3% vs. 42.4%, two: 12.5% vs. 8.5%, p = 0.61), nor the final dose of palbociclib (125 mg: 54.2% vs. 40.7%, 100 mg: 29.2% vs. 27.1%, 75 mg: 16.7% vs. 32.2%, p = 0.17) differed between younger and older patients. Age (<60 vs. ≥60 years) was not associated with the rate of palbociclib dose reductions or discontinuations secondary to neutropenia. Older (≥60 years) patients were more likely to start palbociclib at lower doses which may impact neutropenia and non-neutropenic intolerance.Keywords
This publication has 16 references indexed in Scilit:
- Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studiesEuropean Journal of Cancer, 2018
- Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approvalBreast Cancer Research, 2018
- A single institution experience with palbociclib toxicity requiring dose modificationsBreast Cancer Research and Treatment, 2017
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of Clinical Oncology, 2017
- Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and RecommendationsThe Oncologist, 2017
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerNew England Journal of Medicine, 2016
- Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic ChemotherapiesClinical Cancer Research, 2016
- Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2015
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyThe Lancet Oncology, 2015